030320 the Chromogranin–Secretogranin Family
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Uncorrected Author Proof Boller Et Al
Journal of Parkinson’s Disease xx (2020) x–xx 1 DOI 10.3233/JPD-202323 IOS Press 1 Review 2 Neuropathological and Biomarker Findings 3 in Parkinson’s Disease and Alzheimer’s 4 Disease: From Protein Aggregates to 5 Synaptic Dysfunction a,b,∗ c,d,e,∗ 6 Yaroslau Compta and Tamas Revesz a 7 Parkinson’s disease & Movement Disorders Unit, Neurology Service, Hospital Cl´ınic / IDIBAPS / CIBERNED, 8 Barcelona, Catalonia, Spain b 9 Institut de Neuroci`encies, Maextu’s excellence center, University of Barcelona, Barcelona, Catalonia, Spain c 10 Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neurosciences, 11 UCL Queen Square Institute of Neurology, University College London, UK d 12 Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, UK 13 eDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College 14 London, UK Accepted 9 November 2020 15 Abstract. 16 There is mounting evidence that Parkinson’s disease (PD) and Alzheimer’s disease (AD) share neuropathological hallmarks, 17 while similar types of biomarkers are being applied to both. In this review we aimed to explore similarities and differences 18 between PD and AD at both the neuropathology and the biomarker levels, specifically focusing on protein aggregates 19 and synapse dysfunction. Thus, amyloid- peptide (A) and tau lesions of the Alzheimer-type are common in PD and 20 ␣-synuclein Lewy-type aggregates are frequent findings in AD. Modern neuropathological techniques adding to routine 21 immunohistochemistry might take further our knowledge of these diseases beyond protein aggregates and down to their 22 presynaptic and postsynaptic terminals, with potential mechanistic and even future therapeutic implications. -
Limited Diagnostic Utility of Chromogranin a Measurements in Workup of Neuroendocrine Tumors
diagnostics Article Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors Jonas Baekdal 1,2,*, Jesper Krogh 1,2, Marianne Klose 1,2, Pernille Holmager 1,2, Seppo W. Langer 1,3, Peter Oturai 1,4,5, Andreas Kjaer 1,4,5 , Birgitte Federspiel 1,6, Linda Hilsted 1,7, Jens F. Rehfeld 1,7, Ulrich Knigge 1,2,8 and Mikkel Andreassen 1,2 1 ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark; [email protected] (J.K.); [email protected] (M.K.); [email protected] (P.H.); [email protected] (S.W.L.); [email protected] (P.O.); [email protected] (A.K.); [email protected] (B.F.); [email protected] (L.H.); [email protected] (J.F.R.); [email protected] (U.K.); [email protected] (M.A.) 2 Department of Endocrinology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark 3 Department of Oncology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark 4 Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Copenhagen University Hospital, 2100 Copenhagen, Denmark 5 Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, 2100 Copenhagen, Denmark 6 Department of Pathology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark 7 Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark 8 Department of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark * Correspondence: [email protected]; Tel.: +45-6013-4687 Received: 11 October 2020; Accepted: 28 October 2020; Published: 29 October 2020 Abstract: Background: Plasma chromogranin A (CgA) is related to tumor burden and recommended in the follow-up of patients diagnosed with neuroendocrine tumors (NETs). -
Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver Matthew G
Published OnlineFirst January 26, 2018; DOI: 10.1158/1078-0432.CCR-17-3646 CCR Translations Clinical Cancer Research Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver Matthew G. Oser1,2 and Pasi A. Janne€ 1,2,3 Small-cell neuroendocrine cancers often originate in the lung SCCB and SCLC share common genetic driver mutations. but can also arise in the bladder or prostate. Phenotypically, Clin Cancer Res; 24(8); 1775–6. Ó2018 AACR. small-cell carcinoma of the bladder (SCCB) shares many simi- See related article by Chang et al., p. 1965 larities with small-cell lung cancer (SCLC). It is unknown whether In this issue of Clinical Cancer Research, Chang and colleagues ponent, suggesting that RB1 and TP53 loss occurs after the initial (1) perform DNA sequencing to characterize the mutational development of the urothelial carcinoma and is required for signature of small-cell carcinoma of the bladder (SCCB). They transdifferentiation from urothelial cancer to SCCB. This is rem- find that both SCCB and small-cell lung cancer (SCLC) harbor iniscent of a similar phenomenon observed in two other tumors near universal loss-of-function mutations in RB1 and TP53.In types: (i) EGFR-mutant lung cancer and (ii) castration-resistant contrast to the smoking mutational signature found in SCLC, prostate cancer, where RB1 and TP53 loss is necessary for the SCCB has an APOBEC mutational signature, a signature also transdifferentiation from an adenocarcinoma to a small-cell neu- found in urothelial carcinoma. Furthermore, they show that SCCB roendocrine tumor. EGFR-mutant lung cancers acquire RB1 loss as and urothelial carcinoma share many common mutations that are a mechanism of resistance to EGFR tyrosine kinase inhibitors (3), distinct from mutations found in SCLC, suggesting that SCCB and castration-resistant prostate cancers acquire RB1 and TP53 may arise from a preexisting urothelial cancer. -
Chromogranin a Regulation of Obesity and Peripheral Insulin Sensitivity
MINI REVIEW published: 08 February 2017 doi: 10.3389/fendo.2017.00020 Chromogranin A Regulation of Obesity and Peripheral Insulin Sensitivity Gautam K. Bandyopadhyay1 and Sushil K. Mahata1,2* 1 Department of Medicine, University of California San Diego, La Jolla, CA, USA, 2 Department of Medicine, Metabolic Physiology and Ultrastructural Biology Laboratory, VA San Diego Healthcare System, San Diego, CA, USA Chromogranin A (CgA) is a prohormone and granulogenic factor in endocrine and neuroendocrine tissues, as well as in neurons, and has a regulated secretory pathway. The intracellular functions of CgA include the initiation and regulation of dense-core granule biogenesis and sequestration of hormones in neuroendocrine cells. This protein is co-stored and co-released with secreted hormones. The extracellular functions of CgA include the generation of bioactive peptides, such as pancreastatin (PST), vaso- statin, WE14, catestatin (CST), and serpinin. CgA knockout mice (Chga-KO) display: (i) hypertension with increased plasma catecholamines, (ii) obesity, (iii) improved hepatic Edited by: insulin sensitivity, and (iv) muscle insulin resistance. These findings suggest that individual Gaetano Santulli, CgA-derived peptides may regulate different physiological functions. Indeed, additional Columbia University, USA studies have revealed that the pro-inflammatory PST influences insulin sensitivity and Reviewed by: Anne-Francoise Burnol, glucose tolerance, whereas CST alleviates adiposity and hypertension. This review will Institut national de la santé et de la focus on the different metabolic roles of PST and CST peptides in insulin-sensitive and recherche médicale, France Marialuisa Appetecchia, insulin-resistant models, and their potential use as therapeutic targets. Istituti Fisioterapici Ospitalieri (IRCCS), Italy Keywords: obesity, insulin resistance, inflammation, chromogranin A knockout, pancreastatin, catestatin Hiroki Mizukami, Hirosaki University, Japan *Correspondence: INTRODUCTION Sushil K. -
Identification of VGF Nerve Growth Factor Inducible-Producing Cells In
Int. J. Med. Sci. 2020, Vol. 17 480 Ivyspring International Publisher International Journal of Medical Sciences 2020; 17(4): 480-489. doi: 10.7150/ijms.39101 Research Paper Identification of VGF nerve growth factor inducible-producing cells in human spinal cords and expression change in patients with amyotrophic lateral sclerosis Yasuhiro Noda1, Miruto Tanaka1, Shinsuke Nakamura1, Junko Ito2, Akiyoshi Kakita2, Hideaki Hara1, and Masamitsu Shimazawa1 1. Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan. 2. Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan. Corresponding author: Dr. Masamitsu Shimazawa, Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan. E-mail: [email protected], Telephone and Fax: +81-58-230-8126 © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.08.06; Accepted: 2019.12.23; Published: 2020.02.04 Abstract Amyotrophic lateral sclerosis (ALS) is a serious disease characterized by the degeneration of motor neurons resulting in muscle weakness and paralysis. The neuroendocrine polypeptide VGF is localized in the central nervous system and peripheral endocrine neurons and is cleaved into several polypeptides with multiple functions. Previous studies revealed that VGF was decreased in the cerebrospinal fluid of ALS model mice and sporadic ALS patients. However, it is unknown which cells supply VGF in the spinal cord and a detailed localization is lacking. -
The Chromogranin A-Derived Peptides Catestatin and Vasostatin in Dogs
Höglund et al. Acta Vet Scand (2020) 62:43 https://doi.org/10.1186/s13028-020-00541-3 Acta Veterinaria Scandinavica RESEARCH Open Access The chromogranin A-derived peptides catestatin and vasostatin in dogs with myxomatous mitral valve disease Katja Höglund1* , Jens Häggström2 , Odd Viking Höglund2 , Mats Stridsberg3 , Anna Tidholm2,4 and Ingrid Ljungvall2 Abstract Background: The protein chromogranin A (CgA) is stored and co-released with catecholamines from the stimulated adrenal glands. Increased plasma concentrations of CgA have been shown in people with heart disease. The aim of the study was to investigate whether plasma concentrations of the CgA-derived biologically active peptides catesta- tin and vasostatin were associated with the severity of myxomatous mitral valve disease (MMVD) in dogs and to assess potential associations between these blood variables and dog characteristics, echocardiographic variables, heart rate (HR), blood pressure (BP) and plasma N-terminal-proBNP (NT-proBNP) concentration. Sixty-seven privately owned dogs with or without MMVD were included. The dogs underwent physical examination, blood pressure measurement, blood sample collection, and echocardiographic examination. Plasma concentrations of catestatin and vasostatin were analyzed using radioimmunoassay. Results: Catestatin concentration decreased with increasing left atrial and ventricular size (R 2 0.09, P 0.019), and increased with increasing systolic and diastolic blood pressures (R2 0.08, P 0.038). Regression≤ analyses≤ showed no signifcant associations for vasostatin. No diferences in plasma concentrations≤ ≤ of catestatin or vasostatin were found between the disease severity groups used in the study. Conclusions: In the present dog population, the catestatin concentration showed weak negative associations with left atrial and ventricular sizes, both of which are known to increase with increasing severity of MMVD. -
Neurod1 Regulation of Migration Accompanies the Differential Sensitivity of Neuroendocrine Carcinomas to Trkb Inhibition
OPEN Citation: Oncogenesis (2013) 2, e63; doi:10.1038/oncsis.2013.24 & 2013 Macmillan Publishers Limited All rights reserved 2157-9024/13 www.nature.com/oncsis ORIGINAL ARTICLE NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition JK Osborne1, JE Larsen2, JX Gonzales1, DS Shames2,4, M Sato2,5, II Wistuba3, L Girard1,2, JD Minna1,2 and MH Cobb1 The developmental transcription factor NeuroD1 is anomalously expressed in a subset of aggressive neuroendocrine tumors. Previously, we demonstrated that TrkB and neural cell adhesion molecule (NCAM) are downstream targets of NeuroD1 that contribute to the actions of neurogenic differentiation 1 (NeuroD1) in neuroendocrine lung. We found that several malignant melanoma and prostate cell lines express NeuroD1 and TrkB. Inhibition of TrkB activity decreased invasion in several neuroendocrine pigmented melanoma but not in prostate cell lines. We also found that loss of the tumor suppressor p53 increased NeuroD1 expression in normal human bronchial epithelial cells and cancer cells with neuroendocrine features. Although we found that a major mechanism of action of NeuroD1 is by the regulation of TrkB, effective targeting of TrkB to inhibit invasion may depend on the cell of origin. These findings suggest that NeuroD1 is a lineage-dependent oncogene acting through its downstream target, TrkB, across multiple cancer types, which may provide new insights into the pathogenesis of neuroendocrine cancers. Oncogenesis (2013) 2, e63; doi:10.1038/oncsis.2013.24; published online 19 August 2013 Subject Categories: Cellular oncogenes Keywords: NeuroD1; neuroendocrine; TrkB; migration INTRODUCTION increased expression of NeuroD1, possibly in a lineage-dependent Aberrant expression of basic helix loop helix transcription factors manner. -
The Granin Protein Family in Cardiac Disease
The granin protein family in cardiac disease Helge R. Røsjø, MD1,2,3 1 Division of Medicine, Akershus University Hospital, Lørenskog, Norway 2 Institute of Experimental Medical Research, Oslo University Hospital, Ullevål, Oslo, Norway 3 Center for Heart Failure Research and K.G. Jebsen Cardiac Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway © Helge R. Røsjø, 2012 Series of dissertations submitted to the Faculty of Medicine, University of Oslo No. 1333 ISBN 978-82-8264-359-7 All rights reserved. No part of this publication may be reproduced or transmitted, in any form or by any means, without permission. Cover: Inger Sandved Anfinsen. Printed in Norway: AIT Oslo AS. Produced in co-operation with Unipub. The thesis is produced by Unipub merely in connection with the thesis defence. Kindly direct all inquiries regarding the thesis to the copyright holder or the unit which grants the doctorate. Contents Supported by ......................................................................................................................... 4 Acknowledgments ................................................................................................................ 5 Abbreviations ........................................................................................................................ 8 List of papers in thesis: ....................................................................................................... 10 Introduction ....................................................................................................................... -
Chromogranin a Dependent Upon Interaction with Biogenesis in Mast
Secretogranin III Directs Secretory Vesicle Biogenesis in Mast Cells in a Manner Dependent upon Interaction with Chromogranin A This information is current as of October 4, 2021. Prerna Prasad, Angel A. Yanagihara, Andrea L. Small-Howard, Helen Turner and Alexander J. Stokes J Immunol 2008; 181:5024-5034; ; doi: 10.4049/jimmunol.181.7.5024 http://www.jimmunol.org/content/181/7/5024 Downloaded from References This article cites 42 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/181/7/5024.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 4, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Secretogranin III Directs Secretory Vesicle Biogenesis in Mast Cells in a Manner Dependent upon Interaction with Chromogranin A1 Prerna Prasad,2*§ Angel A. Yanagihara,2‡ Andrea L. Small-Howard,2* Helen Turner,2,3*† and Alexander J. -
Gastrointestinal Stromal Tumors Regularly Express Synaptic Vesicle Proteins: Evidence of a Neuroendocrine Phenotype
Endocrine-Related Cancer (2007) 14 853–863 Gastrointestinal stromal tumors regularly express synaptic vesicle proteins: evidence of a neuroendocrine phenotype Per Bu¨mming, Ola Nilsson1,Ha˚kan Ahlman, Anna Welbencer1, Mattias K Andersson 1, Katarina Sjo¨lund and Bengt Nilsson Lundberg Laboratory for Cancer Research, Departments of Surgery and 1Pathology, Sahlgrenska Academy at the University of Go¨teborg, Sahlgrenska University Hospital, SE-413 45 Go¨teborg, Sweden (Correspondence should be addressed to O Nilsson; Email: [email protected]) Abstract Gastrointestinal stromal tumors (GISTs) are thought to originate from the interstitial cells of Cajal, which share many properties with neurons of the gastrointestinal tract. Recently, we demonstrated expression of the hormone ghrelin in GIST. The aim of the present study was therefore to evaluate a possible neuroendocrine phenotype of GIST. Specimens from 41 GISTs were examined for the expression of 12 different synaptic vesicle proteins. Expression of synaptic-like microvesicle proteins, e.g., Synaptic vesicle protein 2 (SV2), synaptobrevin, synapsin 1, and amphiphysin was demonstrated in a majority of GISTs by immunohistochemistry, western blotting, and quantitative reversetranscriptase PCR. One-third of the tumors also expressed the large dense core vesicle protein vesicular monoamine transporter 1. Presence of microvesicles and dense core vesicles in GIST was confirmed by electron microscopy. The expression of synaptic-like microvesicle proteins in GIST was not related to risk profile or to KIT/platelet derived growth factor alpha (PDGFRA) mutational status. Thus, GISTs regularly express a subset of synaptic-like microvesicle proteins necessary for the regulated secretion of neurotransmitters and hormones. Expression of synaptic-like micro-vesicle proteins, ghrelin and peptide hormone receptors in GIST indicate a neuroendocrine phenotype and suggest novel possibilities to treat therapy-resistant GIST. -
Elevated Serum Chromogranin a Is Detectable in Patients with Carcinomas at Advanced Disease Stages
Annals o f Clinical & Laboratory Science, vol. 30, no. 2, 2000 175 Elevated Serum Chromogranin A is Detectable in Patients with Carcinomas at Advanced Disease Stages James T. Wu,1 Alan J. Erickson,1 Kuo-Chien Tsao,2 Tsu-Lan Wu,2 and Chien-Feng Sun2 1 Department of Pathology, University of Utah School of Medicine, and Associated Regional University Pathologists (ARUP), University of Utah Health Sciences Center, Salt Lake City, Utah 2 Department of Clinical Pathology, Chang Gung Memorial Hospital, Taipei, Taiwan Abstract. Chromogranin A (CgA), a marker of neuroendocrine cells and an indicator for neuroendocrine differentiation, is associated with a poor prognosis when detected in tumor tissue, based on immunohistochemical techniques. We sought to determine whether it is possible to detect elevated serum CgA in patients with commonly occurring carcinomas of non-neuroendocrine origin. CgA was measured in both random and serial serum specimens, using a serum CgA assay developed in our laboratory. Elevated levels of serum CgA were detected in patients with carcinoma of the prostate, breast, ovary, pancreas, and colon. Serum CgA levels in patients with all types of carcinoma appeared to parallel the changes of serum dominant tumor markers and were found in sera containing highly elevated tumor markers. Based on these preliminary findings, perhaps we should monitor CgA, in addition to the routinely used tumor markers, during the treatment of patients with carcinomas to determine if CgA is useful as a prognostic marker in carcinomas other than prostatic cancer. Keywords: Chromogranin A, carcinoma antigens CA-15-3, CA-19-9, CA-125, carcinoembryonic antigen (CEA), prostatic specific antigen (PSA) Introduction CgA has been used to indicate neuroendocrine differentiation, which is a sign of poor prognosis. -
Regulation of Tumor Growth by Circulating Full-Length Chromogranin A
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 45 Research Paper Regulation of tumor growth by circulating full-length chromogranin A Flavio Curnis1,*, Alice Dallatomasina1,*, Mimma Bianco1,*, Anna Gasparri1, Angelina Sacchi1, Barbara Colombo1, Martina Fiocchi1, Laura Perani2, Massimo Venturini2, Carlo Tacchetti2, Suvajit Sen3, Ricardo Borges4, Eleonora Dondossola1, Antonio Esposito2,5, Sushil K. Mahata6 and Angelo Corti1,5 1 Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy 2 Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy 3 University of California, Los Angeles, CA, USA 4 La Laguna University, Tenerife, Spain 5 Vita-Salute San Raffaele University, Milan, Italy 6 VA San Diego Healthcare System and University of California, San Diego, La Jolla, CA, USA * These authors have contributed equally to this work Correspondence to: Flavio Curnis, email: [email protected] Correspondence to: Angelo Corti, email: [email protected] Keywords: chromogranin A, angiogenesis, tumor perfusion, endothelial cells, protease-nexin-1 Received: September 9, 2016 Accepted: September 17, 2016 Published: September 24, 2016 ABSTRACT Chromogranin A (CgA), a neuroendocrine secretory protein, and its fragments are present in variable amounts in the blood of normal subjects and cancer patients. We investigated whether circulating CgA has a regulatory function in tumor biology and progression. Systemic administration of full-length CgA, but not of fragments lacking the C-terminal region, could reduce tumor growth in murine models of fibrosarcoma, mammary adenocarcinoma, Lewis lung carcinoma, and primary and metastatic melanoma, with U-shaped dose-response curves. Tumor growth inhibition was associated with reduction of microvessel density and blood flow in neoplastic tissues.